Need Assistance?

US & Canada:
+
UK: +

Our Highlights

GMP Grade Efficient workshop for GMP production.
Optimal Prices Buying products on this site guarantees the best price!
Commercial Batches Independent GMP manufacturing suites that handle commercial batches
Prompt Delivery Warehouses in multiple cities to ensure timely delivery
Flexible Quantity Quantities available from milligrams to ton

Terlipressin

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Terlipressin is an analog of vasopressin and a partial agonist of the vasopressin V1A receptor (Ki = 0.85 µM). It has been used as a vasoactive drug in the management of low blood pressure.

Category

Peptide Inhibitors

Catalog number

BAT-010058

CAS number

14636-12-5

Molecular Formula

C52H74N16O15S2

Molecular Weight

1227.4

Size	Price	Stock	Quantity
100 mg	$299	In stock

Specification
Reference Reading

IUPAC Name

(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]pyrrolidine-2-carboxamide

Synonyms

glipressin; glycylpressin; glypressin; Remestyp; terlypressin; TGLVP; triglycylvasopressin; triglycyl lysine vasopressin; Terlipressine; Terlipressinum; Terlipressina; Terlipressina; EINECS 238-680-8; LS-161411

Related CAS

1884420-36-3 (diacetate)

Appearance

White Solid

Purity

≥95%

Density

1.46 g/cm3

Boiling Point

1824°C at 760 mmHg

Sequence

GGGC(1)YFQNC(1)PKG

Storage

Store at -20°C

InChI

InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1

InChI Key

BENFXAYNYRLAIU-QSVFAHTRSA-N

Canonical SMILES

C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N

1.[MODERN VIEW ON INTENSIVE THERAPY OF GASTRO-INTESTINAL HEMORRHAGE].

Tutchenko MI, Rudyk DV, Iskra NI, Trofimenko SP, Shchur IV. Klin Khir. 2015 Oct;(10):11-4.

Basing on analysis of the treatment results in 47 patients for gastro-intestinal hemorrhage, the experience of application of a tranexamic acid in a content of infusion therapy and hemaxam per os was adduced. The data obtained witness the expediency of hemaxam application in a content of therapy on the stage of a hemorrhage letup and for the recurrence prevention.

2.Terlipressin and albumin for type 1 hepatorenal syndrome: does bacterial infection affect the response?

Altun R1, Korkmaz M1, Yıldırım E1, Öcal S1, Akbaş E1, Selçuk H1. Springerplus. 2015 Dec 23;4:806. doi: 10.1186/s40064-015-1625-z. eCollection 2015.

Vasoconstrictor therapy with terlipressin and concomitant albumin can improve renal function in patients with hepatorenal syndrome (HRS) type 1, but the efficacy of therapy in patients with active infection is controversial. The aim of this study was to investigate the efficacy, adverse effects, and predictors of terlipressin therapy and to find out whether there was a difference in response rates between the patients with or without active infections. Data of 58 patients with type 1 HRS treated with terlipressin and albumin were retrospectively evaluated. Twenty-six patients (44.8 %) showed complete response to treatment. Response rates of patients with or without active bacterial infection were 47 and 43.9 %, respectively (p > 0.05). Only baseline serum creatinine level was significantly related to response in univariate/multivariate analyses (p < 0.05). Twenty-three patients (39.6 %) developed adverse effects probably related to treatment.

3.Current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding.

Garbuzenko DV1. Curr Med Res Opin. 2016 Mar;32(3):467-75. doi: 10.1185/03007995.2015.1124846. Epub 2016 Jan 25.

OBJECTIVE: Esophageal variceal bleeding is the most dangerous complication in patients with liver cirrhosis, and it is accompanied by high mortality. Their treatment can be complex, and requires a multidisciplinary approach. This review examines current approaches to the management of patients with liver cirrhosis who have acute esophageal variceal bleeding.

4.Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1.

Boyer TD1, Sanyal AJ2, Wong F3, Frederick RT4, Lake JR5, O'Leary JG6, Ganger D7, Jamil K8, Pappas SC9; REVERSE Study Investigators. Gastroenterology. 2016 Feb 16. pii: S0016-5085(16)00217-1. doi: 10.1053/j.gastro.2016.02.026. [Epub ahead of print]

BACKGROUND & AIMS: Hepatorenal syndrome type 1 (HRS-1) in patients with cirrhosis and ascites is a functional, potentially reversible form of acute kidney injury characterized by rapid (<2 weeks) and progressive deterioration of renal function. Terlipressin is a synthetic vasopressin analogue that acts, via vascular vasopressin V1 receptors, as a systemic vasoconstrictor. We performed a phase 3 study to evaluate the efficacy and safety of intravenous terlipressin plus albumin vs placebo plus albumin in patients with HRS-1.